Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The Nasdaq faded while the other indexes fell as Treasury yields keep running higher. Micron rose late on earnings and guidance. The post Dow Jones Futures: Micron Rises On Hot Earnings After Treasury Yields Pressure Stocks appeared first on Investor’s…
Alphabet released its most powerful, artificial intelligence model called Gemini 4 Argon. Google stock climbed on the news. The post Google Stock Rises On Gemini 4 Argon Release After New AI Model Delays appeared first on Investor’s Business Daily.
Micron Technology beat Wall Street’s sky-high targets for its fiscal fourth quarter and with its outlook. Micron stock rose modestly on the news. The post Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above Views appeared first on Investor’s Business…
A district judge ruled Wednesday that Liquidia infringed on United Therapeutics’ patents with its drug, Yutrepia. The stocks diverged. The post United Just Pulled The Ultimate Bull Move, As Its Chief Rival Collapsed appeared first on Investor’s Business Daily.
Welcome to IBD Live! This list of FAQs and useful links will speed your learning curve. The Ready List contains top stocks that meet our fundamental and technical screening criteria… Read More The post IBD Live Q&A Summary, Stock Lists…
SpaceX stock pays no dividend. But traders can craft a trade in the options market that could generate a big annualized yield. The post SpaceX Stock Doesn’t Pay A Dividend. Use This Strategy To Create One. appeared first on Investor’s…
Celestica is above an early entry near 353 within a larger base after strong earnings performance in the second quarter. The post AI Play Celestica Flashes Three Buy Points Amid Strong Earnings Outlook appeared first on Investor’s Business Daily.
Investors seeking a high yield and stable fundamentals in the healthcare sector need look no further than Bristol Myers Squibb. The post This Pharma Giant Has The Right Medicine For Income Investors appeared first on Investor’s Business Daily.
An analyst upgraded Target to a buy rating, telling investors that the retailer’s turnaround is working. The post Analyst Praises Target’s Turnaround As Retailer Keeps Cutting Prices. The Stock Is In A Buy Area. appeared first on Investor’s Business Daily.
Eli Lilly already beat its next-generation weight-loss drug, retatrutide, and it hasn’t even hit the market. The post Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug appeared first on Investor’s Business Daily.
